Drugs for Short Bowel Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 95)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Ursodeoxycholic acid |
Approved, Investigational |
Phase 4 |
|
128-13-2 |
31401
|
Synonyms:
(3a,5b,7b)-3,7-Dihydroxycholan-24-Oate
(3a,5b,7b)-3,7-Dihydroxy-cholan-24-Oate
(3a,5b,7b)-3,7-Dihydroxycholan-24-Oic acid
(3a,5b,7b)-3,7-Dihydroxy-cholan-24-Oic acid
(3alpha,5beta,7beta)-3,7-Dihydroxycholan-24-Oate
(3alpha,5beta,7beta)-3,7-dihydroxycholan-24-oic acid
(3alpha,5beta,7beta)-3,7-Dihydroxycholan-24-Oic acid
(3alpha,5beta,7beta,8xi)-3,7-dihydroxycholan-24-oic acid
(3α,5β,7β)-3,7-dihydroxycholan-24-Oate
(3α,5β,7β)-3,7-dihydroxycholan-24-oic acid
(3α,5β,7β)-3,7-dihydroxycholan-24-Oic acid
(4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
128-13-2
17-beta-(1-Methyl-3-carboxypropyl)etiocholane-3-alpha,7-beta-diol
3 alpha,7 beta Dihydroxy 5 beta cholan 24 Oic acid
3 alpha,7 beta-Dihydroxy-5 beta-cholan-24-oic Acid
3 alpha,7 beta-Dihydroxy-5 beta-cholan-24-Oic acid
3,7-Dihydroxycholan-24-oic acid
3,7-Dihydroxycholan-24-Oic acid
3a,7b-Dihydroxy-5b-cholan-24-Oate
3a,7b-Dihydroxy-5b-cholan-24-Oic acid
3alpha,7beta-Dihydroxy-5beta-cholan-24-Oate
3alpha,7beta-Dihydroxy-5beta-cholan-24-oic acid
3alpha,7beta-Dihydroxy-5beta-cholan-24-Oic acid
3alpha,7beta-Dihydroxy-5beta-cholanic acid
3-alpha,7-beta-Dihydroxy-5-beta-cholanoic acid
3-alpha,7-beta-Dihydroxycholanic acid
3-alpha,7-beta-Dioxycholanic acid
3α,7β-dihydroxy-5β-cholan-24-Oate
3α,7β-dihydroxy-5β-cholan-24-Oic acid
4-10-00-01604 (Beilstein Handbook Reference)
50809-41-1
5beta-Cholan-24-oic acid-3alpha,7beta-diol
5beta-Cholanic Acid-3alpha,7beta-diol
7beta-Hydroxylithocholic acid
7-beta-Hydroxylithocholic acid
80225-86-1
AB00513977
AC-18919
AC1L1LJH
AC-2081
Acid, deoxyursocholic
Acid, ursacholic
Acid, ursodeoxycholic
Acide ursodesoxycholique
Acide ursodesoxycholique [INN-French]
Acido ursodeossicolico
Acido ursodeossicolico [Italian]
Acido ursodeoxicolico
Acido ursodeoxicolico [INN-Spanish]
Acidum ursodeoxycholicum
Acidum ursodeoxycholicum [INN-Latin]
Actigall
Actigall (TN)
Antigall
Antigen brand OF ursodeoxycholic acid
Arsacol
Aventis brand OF ursodeoxycholic acid
Axcan brand OF ursodeoxycholic acid
BB_NC-2372
BPBio1_001052
BRN 3219888
BSPBio_000956
C07880
C24H40O4
CCRIS 5502
CHEBI:9907
CHEMBL1551
CHEMBL73390
chenodeoxycholic acid
Cholan-24-oic acid, 3,7-dihydroxy-, (3-alpha,5-beta,7-beta)- (9CI)
Cholit-ursan
Cholofalk
CID11516715
CID31401
CP Brand OF ursodeoxycholic acid
CPD000058403
CPD-10534
D00734
DB01586
Delursan
Deoxyursocholic acid
Deoxyursocholic Acid
Destolit
Deursil
Dom-ursodiol c
EINECS 204-879-3
Estedi brand OF ursodeoxycholic acid
|
Falk brand OF ursodeoxycholic acid
Farmasa brand OF ursodeoxycholic acid
Galen brand OF ursodeoxycholic acid
Heumann brand OF ursodeoxycholic acid
HMS1570P18
ISO-URSODEOXYCHOLIC ACID
IU5
Litursol
LMST04010033
LS-53033
Lyeton
MLS000028461
MLS001066373
MolPort-001-794-630
MolPort-005-932-884
NCGC00179363-01
NCI60_028904
Niddapharm brand OF ursodeoxycholic acid
Norgine brand OF ursodeoxycholic acid
NSC 657950
NSC 683769
Orphan brand OF ursodeoxycholic acid
Peptarom
PHL-ursodiol c
PMS-ursodiol c
Prestwick0_000958
Prestwick1_000958
Prestwick2_000958
Prestwick3_000958
Provalis brand OF ursodeoxycholic acid
S1643_Selleck
SAM002264653
Sanofi synthelabo brand OF ursodeoxycholic acid
SMP2_000012
SMR000058403
Sodium ursodeoxycholate
Sodium Ursodeoxycholate
Solutrat
SPBio_003105
tramedico Brand OF ursodeoxycholic acid
U0030
U5127_SIGMA
U-9000
UDCA
UDCS
UNII-724L30Y2QR
Urdox
Urosdesoxycholate
Urosdesoxycholic acid
Urosiol
Ursacholic acid
Ursacholic Acid
Ursacol
Urso
UrSO
Urso (TN)
Urso 250
Urso DS
Urso Forte
urso Heumann
Ursobilane
Ursobilin
Ursochol
Ursodamor
Ursodeoxy cholic acid
ursodeoxycholate
Ursodeoxycholate
Ursodeoxycholate, sodium
Ursodeoxycholic acid
URSODEOXYCHOLIC ACID
Ursodeoxycholic acid (JP15/INN)
Ursodeoxycholic acid, UDCA, Ursosan, Ursofalk, Urso Forte, Udiliv, Ursodiol
Ursodeoxycholicacid
Ursodesoxycholic acid
Ursodexycholate
Ursodexycholic acid
Ursodexycholic Acid
ursodiol
Ursodiol
Ursodiol (USP)
Ursodiol [USAN]
Ursofalk
Ursogal
Ursolite
Ursolvan
Ursosan
Vita brand OF ursodeoxycholic acid
Zambon brand OF ursodeoxycholic acid
|
|
2 |
|
Lactulose |
Approved |
Phase 4 |
|
4618-18-2 |
11333
|
Synonyms:
(2S,3R,4S,5R,6R)-2-[(2R,3S,4S,5R)-4,5-Dihydroxy-2,5-bis(hydroxymethyl)oxolan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
4-O-b-D-Galactopyranosyl-D-fructofuranose
4-O-b-D-Galactopyranosyl-D-fructose
4-O-beta-delta-Galactopyranosyl-delta-fructofuranose
4-O-beta-delta-Galactopyranosyl-delta-fructose
4-O-beta-D-Galactopyranosyl-D-fructofuranose
4-O-beta-D-Galactopyranosyl-D-fructose
4-O-β-D-galactopyranosyl-D-fructofuranose
4-O-β-D-galactopyranosyl-D-fructose
Amivalex
|
Bifiteral
Cephulac
delta-Lactulose
D-Lactulose
Duphalac
Lactulosa
Lactulose
Lactulosum
Normase
|
|
3 |
|
Mannitol |
Approved, Investigational |
Phase 4 |
|
69-65-8 |
453
6251
|
Synonyms:
(2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexaol
(2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol
(2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexol
(L)-Mannitol
1,2,3,4,5,6-Hexanehexol
123897-58-5
133-43-7
15719_ALDRICH
15719_RIEDEL
33440_RIEDEL
33440_SIGMA
36413-61-3
4-01-00-02841 (Beilstein Handbook Reference)
5149-40-6
63559_FLUKA
63559_SIGMA
63560_FLUKA
63565_FLUKA
63565_SIGMA
69-65-8
75398-80-0
85085-15-0
87-78-5
AB1002081
AC-12776
AC1L1M49
AC1Q28E5
AI3-19511
Ambap69-65-8
AR-1J3861
bmse000099
BRN 1721898
C00392
C6H14O6
CCRIS 369
CHEBI:16899
CHEMBL689
CID6251
Cordycepate
Cordycepic acid
cpd without stereochemical designation
D-(-)-Mannitol
D00062
D008353
Diosmol
DL-Mannitol
D-mannite
D-mannitol
D-Mannitol
D-Mannitol (JP15)
Dulcite
e 421
e421
e-421
ED1D1E61-FEFB-430A-AFDC-D1F4A957FC3D
EINECS 200-711-8
EINECS 201-770-2
Fraxinine
Hexahydroxyhexane
Hexanhexol
HSDB 714
Invenex
Isotol
LS-1588
LS-89250
M0044
M1902_SIGMA
M4125_SIAL
M8429_SIAL
|
M9546_SIAL
M9647_SIAL
Manicol
manita
Manitol
Maniton S
Maniton-S
Manna sugar
Manna Sugar
Mannazucker
Mannidex
Mannidex 16700
Mannigen
Mannistol
Mannit
Mannit P
Mannite
mannitol
Mannitol
Mannitol (USP)
Mannitol (VAN)
Mannitol [USAN]
Mannitol 10%
Mannitol 10% In Plastic Container
MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER
Mannitol 15%
Mannitol 15% In Plastic Container
MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%
Mannitol 20%
Mannitol 20% In Plastic Container
MANNITOL 25%
Mannitol 5%
Mannitol 5% In Plastic Container
MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%
Mannitolum
Mannogem 2080
Marine crystal
Marine Crystal
MLS001335977
MLS001335978
MolPort-003-927-039
MTL
Mushroom sugar
NCGC00164246-01
NCI-C50362
NSC 407017
NSC 9256
Osmitrol
Osmitrol (TN)
Osmitrol 10% In Water
OSMITROL 10% IN WATER IN PLASTIC CONTAINER
Osmitrol 15% In Water
OSMITROL 15% IN WATER IN PLASTIC CONTAINER
Osmitrol 20% In Water
OSMITROL 20% IN WATER IN PLASTIC CONTAINER
Osmitrol 5% In Water
OSMITROL 5% IN WATER IN PLASTIC CONTAINER
Osmofundin
Osmosal
Resectisol
Resectisol In Plastic Container
SDM no. 35
SDM No. 35
SMR000857324
Sorbitol-Mannitol
SORBITOL-MANNITOL IN PLASTIC CONTAINER
TL806434
UNII-3OWL53L36A
ZINC02041302
|
|
4 |
|
Sitagliptin Phosphate |
|
Phase 4 |
|
|
|
5 |
|
Hypoglycemic Agents |
|
Phase 4,Phase 2 |
|
|
|
6 |
|
Dipeptidyl-Peptidase IV Inhibitors |
|
Phase 4 |
|
|
|
7 |
|
protease inhibitors |
|
Phase 4 |
|
|
|
Synonyms:
|
8 |
|
HIV Protease Inhibitors |
|
Phase 4 |
|
|
|
9 |
|
Glucagon-Like Peptide 1 |
|
Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable |
|
|
|
10 |
|
glucagon |
|
Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable |
|
|
|
11 |
|
Gastrointestinal Agents |
|
Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable |
|
|
|
12 |
|
Hormone Antagonists |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
13 |
|
Hormones, Hormone Substitutes, and Hormone Antagonists |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
14 |
|
Bilirubin |
|
Phase 4,Phase 2,Phase 3 |
|
635-65-4 |
5280352
|
Synonyms:
(4E)2,17-Diethenyl-1,10,19,22,23,24-hexahydro-3,7,13,18-tetramethyl-1,19-dioxo--21H-biline-8,12-dipropanoate
(4E)2,17-Diethenyl-1,10,19,22,23,24-hexahydro-3,7,13,18-tetramethyl-1,19-dioxo--21H-biline-8,12-dipropanoic acid
|
|
|
15 |
|
Hormones |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
16 |
|
Liver Extracts |
|
Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable |
|
|
|
17 |
|
Fat Emulsions, Intravenous |
|
Phase 4,Phase 2,Phase 3,Phase 1 |
|
|
|
18 |
|
Soybean oil, phospholipid emulsion |
|
Phase 4,Phase 3,Phase 2,Phase 1 |
|
|
|
19 |
|
Parenteral Nutrition Solutions |
|
Phase 4,Phase 3,Phase 2,Phase 1 |
|
|
|
20 |
|
Soy Bean |
|
Phase 4,Phase 3,Phase 2,Phase 1 |
|
|
|
21 |
|
Pharmaceutical Solutions |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
22 |
|
Incretins |
|
Phase 4,Phase 1,Phase 2,Not Applicable |
|
|
|
23 |
|
Cholagogues and Choleretics |
|
Phase 4 |
|
|
|
24 |
|
Fibrinolytic Agents |
|
Phase 4 |
|
|
|
25 |
|
Tissue Plasminogen Activator |
|
Phase 4 |
|
|
|
26 |
|
Plasminogen |
|
Phase 4 |
|
|
|
27 |
|
Aspartic Acid |
|
Phase 4 |
|
|
|
28 |
|
alanine |
|
Phase 4,Not Applicable |
|
|
|
29 |
|
N-Methylaspartate |
|
Phase 4 |
|
|
|
30 |
|
glutamine |
|
Phase 4,Not Applicable |
|
|
|
31 |
|
Olive |
|
Phase 4,Phase 3 |
|
|
|
32 |
|
Phytosterol |
|
Phase 4 |
|
|
|
33 |
|
Clindamycin |
Approved, Vet_approved |
Phase 2, Phase 3 |
|
18323-44-9 |
29029
|
Synonyms:
13441-63-9
16669-21-9
18323-44-9
21462-39-5 (mono-hydrochloride)
24620-78-8
24696-19-3
58207-19-5
7 chloro 7 Deoxylincomycin
7(S)-chloro-7-Deoxylincomycin
7(S)-Chloro-7-deoxylincomycin
7-CDL
7-chloro-7-Deoxylincomycin
7-Chloro-7-deoxylincomycin
7-Chlorolincomycin
7-Deoxy-7(S)-chlorolincomycin
AC1L1EGQ
AC1L1GLA
AC1L9JV8
AC1MHD7N
AC1MHE1M
AC1MHUOE
AC1MHX4G
AC1NWAKO
AC1O7ENS
AC1O7GED
AC1OFCIP
AC1OFCIV
AC1OFCJ1
AC1OFCJ7
AC1OIBYJ
AC1OIBYL
AC1OIBYN
AC1Q2V4O
Antirobe
BIDD:GT0418
BPBio1_000236
BRD-A23034328-003-03-4
BSPBio_000214
BSPBio_002049
C06914
C18H33ClN2O5S
CAS-21462-39-5
CHEBI:3745
CHEMBL187
Chlolincocin
Chlorlincocin
Chlorodeoxylincomycin
Chlorolincomycin
CID2786
CID29029
CID3000512
CID3001928
CID3032758
CID3034218
CID446598
CID5702026
CID6602476
CID6604361
CID7048642
CID7048644
CID7048646
CID7048648
CID7276014
CID7276016
CID7276018
CID9812677
CLDM
Cleocin
Cleocin (tn)
Cleocin (TN)
Cleocin Hcl
Cleocin HCl
Cleocin Pediatric
Cleocin Phosphate
Cleocin T
Cleocin T Gel
Cleocin T Lotion
Cleocin T Topical Solution
CLINDA & IL-12
ClindaDerm
Clinda-Derm
Clindagel
Clindamicina
Clindamicina [INN-Spanish]
clindamycin
|
Clindamycin
Clindamycin & Interleukin 12
Clindamycin & VRC3375
Clindamycin (USAN/INN)
Clindamycin [USAN:BAN:INN]
Clindamycin Hcl
Clindamycin hydrochloride
Clindamycin Hydrochloride
Clindamycin monohydrochloride
Clindamycin monohydrochloride, monohydrate
Clindamycin phosphate
Clindamycin Phosphate
Clindamycine
Clindamycine [French]
Clindamycine [INN-French]
Clindamycinum
Clindamycinum [INN-Latin]
Clindesse
Clindets
Clinimycin
CLY
D00277
Dalacin
Dalacin C
Dalacin C Flavored Granules
Dalacin C Phosphate
Dalacin T Topical Solution
Dalacine
DB01190
DivK1c_000464
EINECS 242-209-1
Evoclin
HMS2089A05
HMS2089N16
HSDB 3037
Hydrochloride, clindamycin
I06-0826
IDI1_000464
KBio1_000464
KBio2_000638
KBio2_003206
KBio2_005774
KBio3_001269
KBioGR_000844
KBioSS_000638
Klimicin
Klindan 300
LS-187128
LS-98131
Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-a-D-galacto-octopyranoside
Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-alpha-D-galacto-octopyranoside
Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-α-D-galacto-octopyranoside
MLS001183714
MolPort-002-323-206
MolPort-002-964-479
Monohydrate clindamycin monohydrochloride
Monohydrochloride, clindamycin
Monohydrochloride, monohydrate clindamycin
NCGC00016752-01
NCGC00178843-01
NCGC00179636-01
NINDS_000464
Prestwick0_000137
Prestwick1_000137
Prestwick2_000137
Prestwick3_000137
ResiDerm A
SMP2_000295
SMR000677917
Sobelin
SPBio_000670
SPBio_002153
Spectrum_000158
Spectrum2_000885
Spectrum3_000355
Spectrum4_000292
Spectrum5_001525
STK177246
STOCK1N-31150
U 21251
U-21,251
U-21251
UNII-3U02EL437C
Zindaclin
|
|
34 |
|
Tazobactam |
Approved |
Phase 2, Phase 3 |
|
89786-04-9 |
123630
|
Synonyms:
(2S,3S,5R)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4
(2S,3S,5R)-3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide
(2S,3S,5S)-3-Methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate 4,4-dioxide
(2S,3S,5S)-3-Methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide
89785-84-2
89786-04-9
AC1L3X07
AC-7620
BIDD:GT0212
C07771
CHEBI:100207
CHEMBL404
CID123630
CL298741
|
CL-298741
D00660
DB01606
MolPort-002-500-123
Taszobactam sodium
TAZ
Tazobactam
Tazobactam (JAN/USAN/INN)
Tazobactamum
YTR 830
YTR 830H
YTR-830
YTR830H
YTR-830H
|
|
35 |
|
Metronidazole |
Approved |
Phase 2, Phase 3 |
|
443-48-1 |
4173
|
Synonyms:
1-(2-hydroxy-1-ethyl)-2-methyl-5-nitroimidazole
1-(2-Hydroxy-1-ethyl)-2-methyl-5-nitroimidazole
1-(2-hydroxyethyl)-2-methyl-5-nitroimidazole
1-(2-Hydroxyethyl)-2-methyl-5-nitroimidazole
1-(beta-Ethylol)-2-methyl-5-nitro-3-azapyrrole
1-(beta-Hydroxyethyl)-2-methyl-5-nitroimidazole
1-(beta-Oxyethyl)-2-methyl-5-nitroimidazole
1-(b-Ethylol)-2-methyl-5-nitro-3-azapyrrole
1-(b-Hydroxyethyl)-2-methyl-5-nitroimidazole
1-(b-Oxyethyl)-2-methyl-5-nitroimidazole
1-(β-ethylol)-2-methyl-5-nitro-3-azapyrrole
1-(β-hydroxyethyl)-2-methyl-5-nitroimidazole
1-(β-oxyethyl)-2-methyl-5-nitroimidazole
1-Hydroxyethyl-2-methyl-5-nitroimidazole
2 Methyl 5 nitroimidazole 1 ethanol
2-(2-methyl-5-nitroimidazol-1-yl)ethanol
2-methyl-1-(2-hydroxyethyl)-5-nitroimidazole
2-Methyl-1-(2-hydroxyethyl)-5-nitroimidazole
2-methyl-3-(2-hydroxyethyl)-4-nitroimidazole
2-Methyl-3-(2-hydroxyethyl)-4-nitroimidazole
2-Methyl-5-nitro-1-imidazoleethanol
2-methyl-5-nitroimidazole-1-ethanol
2-Methyl-5-nitroimidazole-1-ethanol
443-48-1
46461_FLUKA
46461_RIEDEL
69198-10-3 (mono-hydrochloride)
99616-64-5
AB00052046
AC-10556
AC1L1HKS
AC1Q2P2Z
Acromona
AKOS000269646
Anagiardil
APMN
Apo-Metronidazole
Arilin
ARONIS24285
Atrivyl
BAS 02983617
BAY-5360
Bayer 5360
BCBcMAP01_000184
Bexon
BIDD:GT0107
Bio-0694
BPBio1_000004
BRD-K52020312-001-05-2
BRN 0611683
BSPBio_000002
BSPBio_002031
CAS-443-48-1
Caswell No. 579AA
CB-01-14 MMX
CCRIS 410
CHEBI:39845
CHEBI:6909
CHEMBL137
CID4173
Clont
CONT
CPD000058175
D00409
Danizol
DB00916
Deflamon
Deflamon-wirkstoff
DivK1c_000007
Efloran
EINECS 207-136-1
Elyzol
Entizol
EPA Pesticide Chemical Code 120401
Eumin
Flagemona
Flagesol
Flagil
Flagyl
Flagyl (TN)
Flagyl 375
Flagyl Er
Flagyl I.V.
Flagyl I.V. RTU
FLAGYL I.V. RTU IN PLASTIC CONTAINER
Flegyl
Florazole
Fossyol
Giatricol
Ginefla vir
Gineflavir
giniflavir
HMS1568A04
HMS1920N19
HMS2051G07
HMS2090B19
HMS2091F14
HMS500A09
HMS547C19
HSDB 3129
Hydrochloride, metronidazole
I14-0667
IDI1_000007
IDR-90105
KBio1_000007
KBio2_001515
KBio2_004083
KBio2_006651
KBio3_001531
KBioGR_000559
KBioSS_001515
Klion
Klont
LS-1264
M0924
M1547_SIGMA
M3761_FLUKA
M3761_SIGMA
M9036_SIGMA
Maybridge1_001999
Meronidal
Methronidazole
Methyl-5-nitroimidazole-1-ethanol
Metric
Metric 21
Metro Cream
Metro Gel
|
METRO I.V
Metro I.V.
Metro I.V. In Plastic Container
MetroCream
Metrodzhil
MetroGel
MetroGel-Vaginal
Metrogel-vaginal (TN)
Metrogyl
Metrolag
MetroLotion
Metrolyl
Metromidol
Metronidaz
Metronidazol
Metronidazol [INN-Spanish]
metronidazole
Metronidazole (JP15/USP/INN)
Metronidazole [USAN:INN:BAN:JAN]
Metronidazole benzoate
Metronidazole hydrochloride
Metronidazole in plastic container
Metronidazole in Plastic Container
Metronidazole monohydrochloride
Metronidazole Monohydrochloride
Metronidazole phosphate
Metronidazole phosphoester
Metronidazole Phosphoester
METRONIDAZOLE USP
Metronidazolo
Metronidazolo [DCIT]
Metronidazolum
Metronidazolum [INN-Latin]
Metrotop
Metrozine
Metryl
Mexibol
Mexibol 'silanes'
MLS000028590
MLS000758286
MolPort-000-141-892
MolPort-002-502-101
Monagyl
Monasin
Monohydrochloride, metronidazole
Nalox
NCGC00016446-01
NCGC00016446-02
NCGC00022059-03
NCGC00022059-04
NCGC00022059-05
NCIOpen2_000337
neo-Tric
NIDA
Nidagel
NINDS_000007
Noritate
Noritate (TN)
Novonidazol
NSC 50364
NSC 69587
NSC50364
NSC-50364
NSC69587
Orvagil
Phosphate, metronidazole
Phosphoester, metronidazole
Prestwick_334
Prestwick0_000081
Prestwick1_000081
Prestwick2_000081
Prestwick3_000081
Protostat
Rathimed
Rosased
RP 8823
RP-8823
S1907_Selleck
SAM001247010
Sanatrichom
Satric
SBB041018
SC 10295
SMP1_000189
SMR000058175
SPBio_000666
SPBio_001941
Spectrum_001035
SPECTRUM1500412
Spectrum2_000883
Spectrum3_000506
Spectrum4_000060
Spectrum5_001289
STK177359
Takimetol
Trichazol
Trichex
Tricho cordes
Trichocide
Tricho-gynaedron
Trichomol
Trichomonacid 'pharmachim'
Trichopal
Trichopol
Tricocet
Tricom
Tricowas B
Trikacide
Trikamon
Trikojol
Trikozol
Trimeks
Trivazol
UNII-140QMO216E
Vagilen
Vagimid
Vandazole
Vertisal
Wagitran
WLN: T5N CNJ A2Q B1 ENW
WLN: T5N CNJA2Q B1 ENW
WLN: T6NTJ DQ ANU1- ET5N CNJ A1 BNW
Zadstat
ZERO/004064
Zidoval
ZINC00113442
|
|
36 |
|
Piperacillin |
Approved |
Phase 2, Phase 3 |
|
66258-76-2 |
43672
|
Synonyms:
(2S-(2alpha,5alpha,6beta(S*)))-6-(((((4-Ethyl-2,3-dioxopiperazin-1-yl)carbonyl)amino)phenylacetyl)amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid
(2S,5R,6R)-6-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
(2S,5R,6R)-6-{[(2R)-2-{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
(2S,5R,6R)-6-{[(2R)-2-{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
4-ethyl-2,3-dioxopiperazine carbonyl ampicillin
59703-84-3
59703-84-3 (mono-hydrochloride salt)
6-(D-(-)-alpha-(4-Ethyl-2,3-dioxo-1-piperazinecarboxamido)phenylacetamido)penicillanic acid
61477-96-1
6beta-{(2R)-2-[(4-ethyl-2,3-dioxopiperazin-1-yl)carboxamido]-2-phenylacetamido}-2,2-dimethylpenam-3alpha-carboxylic acid
AB piperacillin
AB-piperacillin
AC1L2ACR
AC1Q5QXJ
AHP brand OF piperacillin sodium
Astrapin brand OF piperacillin sodium
BIDD:GT0167
BPBio1_000848
BRD-K86873305-236-03-0
BSPBio_000770
C14034
C23H27N5O7S
CCRIS 7362
CHEBI:8232
CHEMBL702
CID43672
Cl-227193
Curasan brand OF piperacillin sodium
D08380
EINECS 262-811-8
Fresenius brand OF piperacillin sodium
Hexal brand OF piperacillin sodium
HMS2090H19
Lederle brand OF pipracillin sodium
LS-149794
Monosodium salt, piperacillin
Peperacillin
Peracin
Peracin (TN)
|
PIPC
Pipcil
Pipera hameln
Piperacilina
piperacillin
Piperacillin
Piperacillin (anhydrous)
Piperacillin (INN)
Piperacillin anhydrous
Piperacillin Anhydrous
Piperacillin curasan
Piperacillin fresenius
Piperacillin hexal
Piperacillin monosodium salt
Piperacillin Monosodium Salt
Piperacillin ratiopharm
Piperacillin sodium
PIPERACILLIN SODIUM
Piperacillina
Pipéracilline
Piperacillin-ratiopharm
Piperacillinum
Pipera-hameln
Pipercillin
Pipracil
Pipracil, Piper
Pipril
Prestwick0_000755
Prestwick1_000755
Prestwick2_000755
Prestwick3_000755
Ratiopharm brand OF piperacillin sodium
Salt, piperacillin monosodium
Sodium, piperacillin
SPBio_002709
T-1220
UNII-9I628532GX
Wyeth brand OF piperacillin sodium
|
|
37 |
|
Ampicillin |
Approved, Vet_approved |
Phase 2, Phase 3 |
|
69-53-4 |
6249
|
Synonyms:
(2S,5R,6R)-6-[[(2R)-2-amino-2-Phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
(2S,5R,6R)-6-{[(2R)-2-amino-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
(2S,5R,6R)-6-{[(2R)-2-amino-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
(2S,5R,6R)-6-{[(2R)-2-amino-2-phenylethanoyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
(2S,5R,6R)-6-{[(2R)-2-amino-2-phenylethanoyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylIC ACID
(2S,6R)-6-{[(2R)-2-amino-2-phenylethanoyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
1h8s
33604-21-6
37234-64-3
47355-94-2
50584-05-9
6-(a-aminophenylacetamido)Penicillanic acid
6-(D(-)-alpha-aminophenylacetamido)Penicillanic acid
6-(D(-)-alpha-Aminophenylacetamido)penicillanic acid
6-(D-(2-amino-2-phenylacetamido))-3,3-Dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylate
6-(D-(2-amino-2-phenylacetamido))-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid
6-(D-(2-amino-2-phenylacetamido))-3,3-Dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid
6-[(Aminophenylacetyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 9ci
69-52-3 (mono-hydrochloride salt)
69-53-4
6beta-[(2R)-2-amino-2-phenylacetamido]-2,2-dimethylpenam-3alpha-carbonyl
6beta-[(2R)-2-amino-2-phenylacetamido]-2,2-dimethylpenam-3alpha-carboxylic acid
6-D(-)-alpha-aminophenylacetamido-Penicillanic acid
7177-48-2 (TRIHYDRATE)
800-79-3
8056-87-9
96707-69-6
98520-55-9
A9393_SIGMA
ABPC
AB-PC
AB-PC Sol
AC-14075
AC1L1M46
Acillin
Adobacillin
Alpen
alpha-Aminobenzylpenicillin
Amblosin
Amcill
Amfipen
Amfipen V
Aminobenzyl penicillin
Aminobenzylpenicillin
Amipenix S
AMP
Ampen
AMPI
Ampi-bol
Ampichel
Ampicil
Ampicilina
Ampicilina [INN-Spanish]
ampicillanyl
ampicillin
Ampicillin
Ampicillin (anhydrous)
AMPICILLIN (SEE ALSO AMPICILLIN TRIHYDRATE 7177-48-2)
Ampicillin (USP/INN)
Ampicillin [USAN:BAN:INN:JAN]
Ampicillin [USAN:INN:BAN:JAN]
Ampicillin A
Ampicillin acid
Ampicillin Acid
Ampicillin anhydrate
Ampicillin anhydrous
Ampicillin Anhydrous
Ampicillin base
Ampicillin Base
Ampicillin sodium
Ampicillin trihydrate
Ampicillin, anhydrous
Ampicillina
Ampicillina [DCIT]
Ampicilline
Ampicilline [INN-French]
Ampicillinum
Ampicillinum [INN-Latin]
Ampicin
Ampi-co
Ampi-Co
Ampifarm
Ampikel
Ampimed
Ampipenin
Ampipenin, nt3
Ampiscel
Ampisyn
Ampi-tab
Ampi-Tab
Ampivax
Ampivet
Amplacilina
Amplin
Amplipenyl
Amplisom
Amplital
Ampy-Penyl
anhydrous ampicillin
Anhydrous ampicillin
Anhydrous ampicillin (JP15)
Antibiotic KS R1
Antibiotic KS-R1
AP
Austrapen
AY 6108
AY 6108
AY-6108
BA 7305
Bayer 5427
BIDD:GT0184
Binotal
Bonapicillin
BPBio1_000142
Britacil
BRL 1341
BRL-1341
BSPBio_000128
BSPBio_001862
C06574
Campicillin
CHEBI:28971
CHEBI:53713
CHEMBL174
CID6249
Cimex
Copharcilin
D-(-)-6-(a-aminophenylacetamido)Penicillanate
D-(-)-6-(a-aminophenylacetamido)Penicillanic acid
D-(-)-6-(alpha-aminophenylacetamido)Penicillanate
D-(-)-6-(alpha-aminophenylacetamido)Penicillanic acid
D-(-)-6-(alpha-Aminophenylacetamido)penicillanic acid
D-(-)-6-(α-aminophenylacetamido)penicillanate
D-(-)-6-(α-aminophenylacetamido)penicillanic acid
D-(−)-6-(α-aminophenylacetamido)penicillanic acid
D-(-)-alpha-Aminobenzylpenicillin
D-(-)-alpha-Aminopenicillin
D-(−)-ampicillin
D-(-)-Ampicillin
D00204
|
D-a-Aminobenzylpenicillin
D-Ampicillin
DB00415
D-Cillin
Delcillin
Deripen
Divercillin
DivK1c_000466
Doktacillin
Duphacillin
EINECS 200-709-7
Geocillin
Grampenil
Guicitrina
Guicitrine
HI 63
HMS2090I11
HSDB 3009
IDI1_000466
KBio1_000466
KBio2_000430
KBio2_002998
KBio2_005566
KBio3_001362
KBioGR_000598
KBioSS_000430
KS-R1
KS-R1, Antibiotic
Lifeampil
LS-1586
LS-169948
Magnapen
Marcillin
MLS000028405
MLS001074168
MolPort-001-794-635
Morepen
NCGC00023282-05
NCGC00023282-06
NINDS_000466
Norobrittin
novo-Ampicillin
Novo-ampicillin
NSC 528986
NSC528986
NSC-528986
Nuvapen
Olin kid
Olin Kid
Omnipen
OMNIPEN (AMPICILLIN)
Omnipen (TN)
Omnipen-N
Orbicilina
P 50
P-50
Pen a
Pen A
Pen A Oral
Pen ampil
Pen Ampil
Penbristol
Penbritin
Penbritin paediatric
Penbritin syrup
Penbritin-S
Penbrock
Penicillin, aminobenzyl
Penicillin, Aminobenzyl
Penicline
Penimic
Pensyn
Pentrex
Pentrexl
Pentrexyl
Pentritin
Pfizerpen a
Pfizerpen A
Pfizerpen-A
Polycillin
Polycillin-N
Polyflex (Veterinary)
Ponecil
Prestwick0_000114
Prestwick1_000114
Prestwick2_000114
Prestwick3_000114
Princillin
Principen
Principen '125'
Principen '250'
Principen '500'
Qidamp
QIDamp
Racenacillin
ro-Ampen
Ro-Ampen
Rosampline
Roscillin
SBB063111
Semicillin
Semicillin R
Servicillin
SK-Ampicillin
SMP1_000211
SMR000058352
Sodium, ampicillin
SPBio_000818
SPBio_002067
Spectrum_000050
Spectrum2_000769
Spectrum3_000301
Spectrum4_000149
Spectrum5_000814
SQ 17382
Sumipanto
Supen
Synpenin
Texcillin
Tokiocillin
Tolomol
Totacillin
Totacillin (sodium)
Totacillin-N
Totalciclina
Totapen
Trifacilina
Trihydrate, ampicillin
Ukapen
Ultrabion
Ultrabron
UNII-7C782967RD
Vampen
Viccillin
Viccillin S
Vidocillin
Vidopen
WY-5103
Wypicil
|
|
38 |
|
Atosiban |
Approved, Investigational |
Phase 2, Phase 3 |
|
90779-69-4 |
|
39 |
|
Loperamide |
Approved |
Phase 3,Phase 1 |
|
53179-11-6 |
3955
|
Synonyms:
2-methoxyethyl1-methylethyl2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
34552-83-5 (mono-hydrochloride)
4-(4-Chlorophenyl)-N,N-dimethyl-.alpha.,.alpha.-diphenyl-4-hydroxy-1-piperidinebutanamide
4-(4-Chlorophenyl)-N,N-dimethyl-alpha,alpha-diphenyl-4-hydroxy-1-piperidinebutanamide
4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide
5-21-02-00379 (Beilstein Handbook Reference)
53179-11-6
AB00053697
AC1L1H38
AKOS000573892
apo-Loperamide
Apo-Loperamide
BAS 01889668
Bio1_000082
Bio1_000571
Bio1_001060
Bio2_000101
Bio2_000581
BPBio1_000274
BRD-K61250553-001-02-9
BRD-K61250553-003-05-8
BRN 1558273
BSPBio_000248
BSPBio_001381
BSPBio_002769
C07080
C29H33ClN2O2
CAS-34552-83-5
CBiol_001796
CHEBI:162259
CHEBI:6532
CHEMBL841
CID3955
D08144
DB00836
Diamide (TN)
Diarr-Eze
DivK1c_000215
EINECS 258-416-5
HMS1791F03
HMS1989F03
HMS2089C13
Hydrochloride, loperamide
IDI1_000215
IDI1_033851
Imodium
Imodium a-D
Imodium a-D caplets
Imodium A-D Caplets
Ioperamide
Kaopectate II
KBio1_000215
KBio2_000101
KBio2_000854
KBio2_002669
KBio2_003422
KBio2_005237
KBio2_005990
KBio3_000201
KBio3_000202
|
KBio3_001989
KBioGR_000101
KBioGR_001685
KBioSS_000101
KBioSS_000854
L000709
Lopac0_000708
Lopac-L-4762
Loperacap
Loperamid
Loperamida
Loperamida [INN-Spanish]
loperamide
Lopéramide
Loperamide (INN)
Loperamide [INN:BAN]
Loperamide hydrochloride
Loperamide monohydrochloride
Loperamide Monohydrochloride
Loperamidum
Loperamidum [INN-Latin]
LS-114352
Maalox anti-diarrheal
Maalox Anti-Diarrheal
MolPort-001-969-016
Monohydrochloride, loperamide
NCGC00015608-01
NCGC00015608-08
NCGC00016828-01
NCGC00024818-01
NCGC00024818-02
NCGC00024818-03
NCGC00024818-04
NCGC00024818-05
nchembio.559-comp8
nchembio.79-comp7
NINDS_000215
Nu-loperamide
Nu-Loperamide
Oprea1_109220
Pepto Diarrhea Control
PMS-Loperamide
Prestwick0_000144
Prestwick1_000144
Prestwick2_000144
Prestwick3_000144
R-18553
rho-Loperamide
Rho-Loperamide
SPBio_001816
SPBio_002187
Spectrum_000374
Spectrum2_001738
Spectrum3_001015
Spectrum4_001143
Spectrum5_001374
ST095179
Tocris-0840
UNII-6X9OC3H4II
|
|
40 |
|
Omega 3 Fatty Acid |
|
Phase 3,Phase 2,Phase 1 |
|
|
|
41 |
|
Anti-Infective Agents |
|
Phase 2, Phase 3 |
|
|
|
42 |
|
Antibiotics, Antitubercular |
|
Phase 2, Phase 3 |
|
|
|
43 |
|
Penicillanic Acid |
|
Phase 2, Phase 3 |
|
|
|
44 |
|
Clindamycin phosphate |
|
Phase 2, Phase 3 |
|
|
|
45 |
|
Antitubercular Agents |
|
Phase 2, Phase 3 |
|
|
|
46 |
|
Antiprotozoal Agents |
|
Phase 2, Phase 3 |
|
|
|
47 |
|
Gentamicins |
|
Phase 2, Phase 3 |
|
|
|
48 |
|
Piperacillin, tazobactam drug combination |
|
Phase 2, Phase 3 |
|
|
|
49 |
|
Antiparasitic Agents |
|
Phase 2, Phase 3 |
|
|
|
50 |
|
Clindamycin palmitate |
|
Phase 2, Phase 3 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 105)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
The Use of DPP-4 Inhibitors in Short Bowel Syndrome |
Unknown status |
NCT02653131
|
Phase 4 |
Dipeptidyl peptidase-4 inhibitor |
2 |
Short Bowel Syndrome and Teduglutide Versus Placebo |
Completed |
NCT02099084
|
Phase 4 |
Teduglutide;Placebo |
3 |
The Preventative and Therapeutical Effect of Ursodeoxycholic Acid(UDCA) to Short Bowel Syndrome Patients |
Completed |
NCT01974336
|
Phase 4 |
ursodeoxycholic acid |
4 |
rtPA in in the Prevention of CVAD-Associated Thrombosis and Infection in Pediatric Patients With Short Bowel Syndrome |
Completed |
NCT02355743
|
Phase 4 |
rtPA lock therapy |
5 |
rHGH and Intestinal Permeability in Intestinal Failure |
Completed |
NCT01380366
|
Phase 4 |
Somatropin |
6 |
Characterization of the Long-term Safety, Efficacy, and Pharmacodynamics Revestive® in the Management of Short Bowel Syndrome Pediatric Patients |
Not yet recruiting |
NCT03562130
|
Phase 4 |
Teduglutide |
7 |
Evaluate the Efficacy and Safety Growth Hormone, Glutamine and Diet in Patients With Short Bowel Syndrome (SBS) |
Terminated |
NCT00742157
|
Phase 4 |
Growth Hormone |
8 |
Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion |
Terminated |
NCT02476994
|
Phase 4 |
Clinolipid;Intralipid |
9 |
Exenatide on GI Motor Function and Permeability in Short Bowel Syndrome |
Withdrawn |
NCT01818648
|
Phase 4 |
Exenatide;Placebo |
10 |
SMOFLipid in Patients Who Are Intralipid Intolerant |
Withdrawn |
NCT03054948
|
Phase 4 |
SMOFLipid;Standard therapy |
11 |
Evaluation of the Efficacy and Safety of Recombinant Human Growth Hormone (rhGH) in the Treatment of Children With Short Bowel Syndrome |
Completed |
NCT00169637
|
Phase 3 |
rhGH |
12 |
Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition |
Completed |
NCT02682381
|
Phase 3 |
Teduglutide 0.05mg/kg;Teduglutide 0.025 mg/kg |
13 |
Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome |
Completed |
NCT00081458
|
Phase 3 |
Placebo;Teduglutide 0.05 mg/kg/d;Teduglutide 0.1 mg/kg/d |
14 |
Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects |
Completed |
NCT00798967
|
Phase 3 |
teduglutide;placebo |
15 |
A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome |
Completed |
NCT01952080
|
Phase 3 |
teduglutide |
16 |
Open-Label Study of Teduglutide for Subjects With PN-Dependent Short Bowel Syndrome (SBS) |
Completed |
NCT00930644
|
Phase 3 |
teduglutide |
17 |
Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Teduglutide in Japanese Subjects With PN-dependent Short Bowel Syndrome (SBS) |
Completed |
NCT02340819
|
Phase 3 |
Teduglutide |
18 |
Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458) |
Completed |
NCT00172185
|
Phase 3 |
teduglutide 0.05 mg/kg/d;teduglutide 0.10 mg/kg/d |
19 |
A One-Year, Open-Label Study With Teduglutide for Subjects Who Completed Study CL0600-021 |
Completed |
NCT01560403
|
Phase 3 |
Teduglutide |
20 |
Impact of SPN on Infection Rate, Duration of Mechanical Ventilation & Rehabilitation in ICU Patients |
Completed |
NCT00802503
|
Phase 3 |
|
21 |
Antibiotic Safety (SCAMP) |
Completed |
NCT01994993
|
Phase 2, Phase 3 |
ampicillin and metronidazole and gentamicin;ampicillin and gentamicin and clindamycin;gentamicin and Piperacillin- tazobactam;standard of care antibiotics and metronidazole;metronidazole, clindamycin, or piperacillin-tazobactam |
22 |
Safety, Efficacy and Pharmacokinetic Study of Teduglutide in Infants 4 to 12 Months of Age With Short Bowel Syndrome |
Recruiting |
NCT03571516
|
Phase 3 |
Teduglutide |
23 |
A Study in Japanese Children With Short Bowel Syndrome Who Completed SHP633-302 |
Recruiting |
NCT03268811
|
Phase 3 |
Teduglutide |
24 |
Study in Japanese Pediatric Subjects With Short Bowel Syndrome (SBS) Who Are Dependent on Parenteral Support |
Recruiting |
NCT02980666
|
Phase 3 |
Teduglutide |
25 |
Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS |
Recruiting |
NCT03690206
|
Phase 3 |
glepaglutide;Placebo |
26 |
Cholestasis Reversal: Efficacy of IV Fish Oil |
Recruiting |
NCT00910104
|
Phase 2, Phase 3 |
Omegaven® |
27 |
Use of Omegaven Fish Oil Emulsion for Parenteral Nutrition Associated Liver Disease in Infants and Children |
Recruiting |
NCT01194063
|
Phase 3 |
Omega-3 fish oil lipid emulsion |
28 |
Compassionate Use of Omegaven in Children |
Recruiting |
NCT02370251
|
Phase 2, Phase 3 |
Omegaven |
29 |
Follow up Study to Assess Long Term Safety and Outcomes in Infants and Children Born to Mothers Participating in Retosiban Treatment Studies |
Recruiting |
NCT02292784
|
Phase 2, Phase 3 |
Retosiban;Atosiban;Placebo |
30 |
Study of Teduglutide in Japanese Participants With Short Bowel Syndrome |
Active, not recruiting |
NCT03663582
|
Phase 3 |
Teduglutide |
31 |
Long-term Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed the TED-C13-003 Study |
Active, not recruiting |
NCT02949362
|
Phase 3 |
Teduglutide |
32 |
Long-term Safety and Efficacy Study of Teduglutide in Pediatric Participants With Short Bowel Syndrome (SBS) |
Active, not recruiting |
NCT02954458
|
Phase 3 |
TED |
33 |
Safety and Efficacy Study in Infant With SBS |
Active, not recruiting |
NCT02865122
|
Phase 2, Phase 3 |
NTRA-9620;Placebo |
34 |
An Extension Study of Teduglutide in Japanese Participants With Short Bowel Syndrome Who Completed 24 Weeks of Treatment in SHP633-306 or TED-C14-004 |
Enrolling by invitation |
NCT03596164
|
Phase 3 |
Teduglutide |
35 |
Comparison of Smoflipid to Soy-based Lipid Reduction for Cholestasis Prevention in Surgical Neonates |
Not yet recruiting |
NCT03387579
|
Phase 3 |
Lipid Emulsions, Intravenous;Intralipid, 20% Intravenous Emulsion |
36 |
Loperamide vs. Placebo's Effect on Ileostomy Output: A Clinical Randomized Blinded Cross-over Study |
Terminated |
NCT02266849
|
Phase 3 |
Loperamide;Placebo |
37 |
A Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Investigational Product MP-101 in Subjects With Short Bowel Syndrome Who Have Had an Inadequate Response to Anti-Diarrheals |
Withdrawn |
NCT02242656
|
Phase 3 |
Opium Tincture USP Deodorized;Opium Tincture USP Deodorized |
38 |
A Open Label Extension Study for Subjects That Complete Study MP-101-CL-001 |
Withdrawn |
NCT02246816
|
Phase 3 |
0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized) |
39 |
Efficacy and Safety of Omega-3 Lipid Therapy in Pediatric Patients With Parenteral Nutrition-Associated Liver Disease |
Unknown status |
NCT01739517
|
Phase 2 |
Omegaven Therapy |
40 |
Can SMOFlipid®, A Composite Parenteral Nutrition Lipid Emulsion, Prevent Progression Of Parenteral Nutrition Associated Liver Disease In Infants? |
Unknown status |
NCT00793195
|
Phase 2 |
Intralipid 20%;SMOFlipid 20% |
41 |
A Phase 2 Trial Testing ZP1848 in Patients With SBS |
Completed |
NCT02690025
|
Phase 2 |
ZP1848 |
42 |
Diet/Growth Factor Mechanisms of Gut Adaptation |
Completed |
NCT00067860
|
Phase 2 |
recombinant human growth hormone |
43 |
Early Supplementation of Enteral Microlipid With and Without Fish Oil in Premature Infants With Enterostomies |
Completed |
NCT01674478
|
Phase 2 |
|
44 |
Use of Pancreatic Enzymes in Short Bowel Syndrome |
Recruiting |
NCT03097029
|
Phase 2 |
Pancreatic Enzyme |
45 |
Safety, Efficacy, PD of FE203799 in Short Bowel Syndrome on Parenteral Support |
Recruiting |
NCT03415594
|
Phase 1, Phase 2 |
FE203799 GLP-2 analogue;FE203799 Placebo GLP-2 analogue;FE203799 GLP-2 analogue |
46 |
Metabolic Balance Study of FE203799 in Patients With SBS With Intestinal Insufficiency |
Recruiting |
NCT03408132
|
Phase 1, Phase 2 |
FE203799 |
47 |
Liraglutide on Decreasing Parenteral Support in Short Bowel Patients (SLIPS) |
Recruiting |
NCT03371862
|
Phase 2 |
Liraglutide Pen Injector [Victoza] |
48 |
Use of Omega 3 Oil Emulsion for Parenteral Nutrition Associated Cholestasis |
Recruiting |
NCT02148146
|
Phase 1, Phase 2 |
Omegaven |
49 |
Omegaven® in the Treatment of Parenteral Nutrition (PN) Induced Liver Injury |
Recruiting |
NCT01845116
|
Phase 2 |
Omegaven® |
50 |
Use of Tocofersolan (Vedrop®) to Prevent or Treat Refractive Vitamin E Deficiency in Infants and Children |
Not yet recruiting |
NCT03582384
|
Phase 2 |
Tocofersolan |
|